PDF(Pubmed)
Abstract：
Since the introduction of rituximab in the late 1990s, significant progress has been made in advancing targeted therapies for B cell lymphomas, improving patients\' chance of being cured and clinicians\' therapeutic armamentarium. A better understanding of disease biology and pathogenic pathways, coupled with refinements in immunophenotypic and molecular diagnostics, have been instrumental in these achievements. While traditional chemotherapy remains fundamental in most cases, concerns surrounding chemorefractoriness and cumulative toxicities, particularly the depletion of the hemopoietic reserve, underscore the imperative for personalized treatment approaches. Integrating targeted agents, notably monoclonal antibodies, alongside chemotherapy has yielded heightened response rates and prolonged survival. A notable paradigm shift is underway with innovative-targeted therapies replacing cytotoxic drugs, challenging conventional salvage strategies like stem cell transplantation. This review examines the landscape of emerging targets for lymphoma cells and explores innovative therapies for diffuse large B cell lymphoma (DLBCL). From Chimeric Antigen Receptor-T cells to more potent monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, checkpoint inhibitors, and small molecules targeting intracellular pathways, each modality offers promising avenues for therapeutic advancement. This review aims to furnish insights into their potential implications for the future of DLBCL treatment strategies.
摘要：
自从20世纪90年代末引入利妥昔单抗以来，在推进B细胞淋巴瘤的靶向治疗方面取得了重大进展，提高患者被治愈的机会和临床医生的治疗性医疗设备。更好地了解疾病生物学和致病途径，再加上免疫表型和分子诊断的改进，在这些成就中发挥了重要作用。虽然传统化疗在大多数情况下仍然是基本的，围绕化学难降解性和累积毒性的担忧，特别是造血储备的消耗，强调个性化治疗方法的必要性。整合目标药物，特别是单克隆抗体，与化疗一起提高了缓解率并延长了生存期.一个值得注意的范式转变正在进行中，创新的靶向疗法取代了细胞毒性药物。挑战传统的抢救策略，如干细胞移植。这篇综述研究了淋巴瘤细胞的新兴靶标，并探索了弥漫性大B细胞淋巴瘤（DLBCL）的创新疗法。从嵌合抗原受体T细胞到更有效的单克隆抗体，抗体-药物缀合物，双特异性抗体，检查点抑制剂，和靶向细胞内途径的小分子，每种方式都为治疗进步提供了有希望的途径。这篇综述旨在提供对DLBCL治疗策略未来潜在影响的见解。
